KaliVir Immunotherapeutics develops oncolytic viral immunotherapy programs for the treatment of cancer.
KaliVir Immunotherapeutics has raised $14.0M in total funding. The most recent round was Series A. The last funding was announced in August 2026.
KaliVir Immunotherapeutics's investors include Flexus Partners, Premier Partners, Nextrans, Company K Partners, SV Investment Corp.
KaliVir Immunotherapeutics is headquartered in Pittsburgh, United States.
KaliVir Immunotherapeutics develops oncolytic viral immunotherapy programs for the treatment of cancer.
KaliVir Immunotherapeutics is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"KaliVir Immunotherapeutics — Funding & Investors." VCBacked, August 19, 2026, https://www.vcbacked.co/company/kalivir-immunotherapeutics. Accessed September 3, 2026.
VCBacked. (2026). KaliVir Immunotherapeutics — Funding & Investors. Retrieved September 3, 2026, from https://www.vcbacked.co/company/kalivir-immunotherapeutics
{{cite web |title=KaliVir Immunotherapeutics — Funding & Investors |url=https://www.vcbacked.co/company/kalivir-immunotherapeutics |website=VCBacked |access-date=September 3, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated